Fulgent Genetics (FLGT) Projected to Post Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) is anticipated to issue its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect Fulgent Genetics to post earnings of $0.02 per share and revenue of $85.38 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

Fulgent Genetics Price Performance

NASDAQ FLGT opened at $23.27 on Friday. The business has a 50 day moving average price of $26.29 and a 200 day moving average price of $24.75. The company has a market capitalization of $719.28 million, a P/E ratio of -16.74 and a beta of 0.86. Fulgent Genetics has a 1-year low of $14.57 and a 1-year high of $31.04.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wall Street Zen cut Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Raymond James Financial restated an “outperform” rating and set a $36.00 target price on shares of Fulgent Genetics in a report on Friday, November 14th. Zacks Research downgraded shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Piper Sandler increased their price target on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.00.

Insiders Place Their Bets

In other news, COO Jian Xie sold 1,198 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $29.57, for a total transaction of $35,424.86. Following the completion of the sale, the chief operating officer directly owned 337,889 shares of the company’s stock, valued at $9,991,377.73. The trade was a 0.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Hanlin Gao sold 1,075 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total value of $30,454.75. Following the completion of the transaction, the insider directly owned 952,890 shares in the company, valued at $26,995,373.70. This trade represents a 0.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 5,572 shares of company stock worth $163,112. 31.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Fulgent Genetics

Several hedge funds have recently modified their holdings of FLGT. ExodusPoint Capital Management LP bought a new stake in shares of Fulgent Genetics in the 4th quarter worth approximately $367,000. Magnetar Financial LLC acquired a new stake in Fulgent Genetics in the fourth quarter worth $321,000. Headlands Technologies LLC lifted its stake in Fulgent Genetics by 26.9% in the fourth quarter. Headlands Technologies LLC now owns 12,046 shares of the company’s stock valued at $316,000 after buying an additional 2,553 shares during the last quarter. Franklin Resources Inc. lifted its stake in Fulgent Genetics by 27.1% in the fourth quarter. Franklin Resources Inc. now owns 13,868 shares of the company’s stock valued at $364,000 after buying an additional 2,955 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in shares of Fulgent Genetics by 11.2% during the third quarter. Mackenzie Financial Corp now owns 12,155 shares of the company’s stock valued at $275,000 after acquiring an additional 1,220 shares during the period. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.